Ocular Therapeutix公司Axpaxli在Sol-1试验中多个次要终点指标达到统计学显著性

美股速递
Apr 13

Ocular Therapeutix公司宣布,其核心产品Axpaxli在关键性的Sol-1临床试验中表现卓越,成功达到了多个预先设定的次要终点指标,且结果均显示出统计学上的显著意义。这一积极数据进一步强化了Axpaxli的疗效证据,为公司后续的监管沟通与市场拓展奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10